Journal article 373 views 109 downloads
A Mathematical Model to Investigate the Effects of Ceralasertib and Olaparib in Targeting the Cellular DNA Damage Response Pathway
Journal of Pharmacology and Experimental Therapeutics, Volume: 387, Issue: 1, Pages: 55 - 65
Swansea University Authors: Kira Pugh, Gibin Powathil
-
PDF | Proof
Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).
Download (1.26MB)
DOI (Published version): 10.1124/jpet.122.001558
Abstract
The ataxia-telangiectasia and Rad3-related (ATR) inhibitor ceralasertib and the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib have shown synergistic activity, in vitro, in the FaDu ATM-KO cell line. It was found that combining these drugs with lower doses and for shorter treatment periods i...
Published in: | Journal of Pharmacology and Experimental Therapeutics |
---|---|
ISSN: | 0022-3565 1521-0103 |
Published: |
American Society for Pharmacology & Experimental Therapeutics (ASPET)
2023
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa63760 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract: |
The ataxia-telangiectasia and Rad3-related (ATR) inhibitor ceralasertib and the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib have shown synergistic activity, in vitro, in the FaDu ATM-KO cell line. It was found that combining these drugs with lower doses and for shorter treatment periods induced greater or equal toxicity in cancer cells than using either as a single agent. Here, we develop a biologically-motivated mathematical model governed by a set of ordinary differential equations, considering the cell cycle-specific interactions of olaparib and ceralasertib. By exploring a range of different possible drug mechanisms, we have studied the effects of their combination as well as which drug interactions are the most prominent. After careful model selection, the model was calibrated and compared to relevant experimental data. We have used this developed model further to investigate other doses of olaparib and ceralasertib in combination, which can be potentially helpful in exploring optimised dosage and delivery. |
---|---|
Keywords: |
Anti-cancer agents, computer modeling and simulation, DNA damage and repair |
College: |
Faculty of Science and Engineering |
Funders: |
KP is supported by EPSRC DTP via Swansea University [Grant EP/T517987/1] |
Issue: |
1 |
Start Page: |
55 |
End Page: |
65 |